

BENZYL ALCOHOL
CAS # 100-51-6
ORAL RISK ASSESSMENT DOCUMENT



NSF International
Ann Arbor, MI
December 2002

Copyright 2002 NSF International

TABLE OF CONTENTS

1.0	INTRODUCTION	1
2.0	PHYSICAL AND CHEMICAL PROPERTIES	3
2.1	Organoleptic Properties	3
3.0	PRODUCTION AND USE.....	4
3.1	Production	4
3.2	Use	4
4.0	ANALYTICAL METHODS	6
4.1	Analyses in Water	6
4.2	Analyses in Biological Matrices	6
5.0	SOURCES OF HUMAN AND ENVIRONMENTAL EXPOSURE	7
5.1	Sources of Human Exposure.....	7
5.2	Sources of Environmental Exposure.....	7
6.0	COMPARATIVE KINETICS AND METABOLISM IN HUMANS AND LABORATORY ANIMALS.....	8
6.1	Absorption	8
6.1.1	<i>Dermal Absorption in Humans</i>	<i>8</i>
6.1.2	<i>Dermal Absorption in Animals.....</i>	<i>8</i>
6.2	Distribution.....	8
6.2.1	<i>Distribution in Humans.....</i>	<i>8</i>
6.2.2	<i>Distribution in Animals</i>	<i>9</i>
6.3	Metabolism	10
6.3.1	<i>Metabolism in Humans.....</i>	<i>10</i>
6.3.2	<i>Metabolism in Animals.....</i>	<i>10</i>
6.4	Elimination/Excretion.....	10
6.4.1	<i>Elimination/Excretion in Humans.....</i>	<i>10</i>
6.4.2	<i>Elimination/Excretion in Animals</i>	<i>11</i>
7.0	EFFECTS ON HUMANS.....	11
7.1	Case Reports.....	11
7.1.1	<i>Effects Resulting From Medicinal Uses.....</i>	<i>11</i>
7.1.2	<i>Irritation and Sensitization.....</i>	<i>15</i>
7.2	Epidemiological Studies.....	17
8.0	EFFECTS ON LABORATORY ANIMALS AND <i>IN VITRO</i> TEST SYSTEMS	17
8.1	Limited-Exposure Effects.....	17

8.1.1	<i>Irritation and Sensitization Studies</i>	17
8.1.2	<i>Ocular Exposure Studies</i>	18
8.2	Single-Exposure Studies	18
8.2.1	<i>In Vivo Studies</i>	18
8.2.2	<i>In Vitro Studies</i>	22
8.3	Short-Term Exposure Studies	23
8.4	Long-Term and Chronic Exposure Studies	25
8.4.1	<i>Subchronic Studies</i>	25
8.4.2	<i>Chronic Studies</i>	26
8.5	Studies of Genotoxicity and Related End-Points	28
8.5.1	<i>Mutagenicity Assays</i>	28
8.5.2	<i>Assays of Chromosomal Damage</i>	29
8.5.3	<i>Other Assays of Genetic Damage</i>	31
8.6	Reproductive and Developmental Toxicity	32
8.7	Studies of Immunological and Neurological Effects	33
9.0	RISK CHARACTERIZATION	34
9.1	Hazard Assessment	34
9.1.1	<i>Evaluation of Major Non-Cancer Effects and Mode of Action</i>	34
9.1.2	<i>Weight-of-Evidence Evaluation and Cancer Characterization</i>	36
9.1.3	<i>Selection of Key Study and Critical Effect</i>	36
9.1.4	<i>Identification of Susceptible Populations</i>	36
9.2	Dose-Response Assessment	36
9.3	Exposure Characterization	37
9.4	TAC Derivation	37
9.5	STEL Derivation	38
10.0	RISK MANAGEMENT	38
10.1	SPAC Derivation	38
11.0	RISK COMPARISONS AND CONCLUSIONS	39
12.0	REFERENCES	40
13.0	APPENDIX	51
13.1	Effects on Lipid Membranes	51
13.1.1	<i>Model Systems</i>	51
13.1.2	<i>Effects on Erythrocytes and Erythrocyte Membranes</i>	52
13.1.3	<i>Effects on Membranes of Renal Origins</i>	56
13.1.4	<i>Effects on Membranes of Gastric and Small Intestine Origin</i>	57
13.1.5	<i>Membranes of Neurological Origin</i>	58

14.0 PEER REVIEW HISTORY..... 58

AUTHORS, PEER REVIEWERS, AND ACKNOWLEDGEMENTS

Author:

NSF Toxicology Services
1.800.NSF.MARK
NSF International
789 Dixboro Road
Ann Arbor, MI 48105

Disclaimer:

The responsibility for the content of this document remains solely with NSF International, and the author noted above should be contacted with comments or for clarification. Mention of trade names, proprietary products, or specific equipment does not constitute an endorsement by NSF International, nor does it imply that other products may not be equally suitable.

Internal NSF Peer Reviewers:

Virunya Bhat, M.S.
Amanda Phelka, M.S.
Clif McLellan, M.S.

External Peer Reviewers:

NSF gratefully acknowledges the efforts of the following experts on the NSF Health Advisory Board in providing peer review. These peer reviewers serve on a voluntary basis, and their opinions do not necessarily represent the opinions of the organizations with which they are affiliated.

Edward Ohanian, Ph.D. (Chairman, NSF Health Advisory Board)
Acting Director, Health and Ecological Criteria Division
Office of Science and Technology/Office of Water
U.S. Environmental Protection Agency

Michael Dourson, Ph.D., DABT (Vice Chairman, NSF Health Advisory Board)
Director
TERA (Toxicology Excellence for Risk Assessment)

David Blakey, D.Phil.
Acting Director, Environmental Health Science
Safe Environments Programme
Health Canada

Randy Deskin, Ph.D., DABT
Director, Toxicology and Product Regulatory Compliance
Cytex Industries, Inc.

Robert Hinderer, Ph.D.
Director of Health, Toxicology, and Product Safety
Noveon, Inc.
Jennifer Orme-Zavaleta, M.S.
Associate Director for Science
USEPA/NHEERL/WED

Adi Pour, Ph.D.
Director, Douglas County Health Department
Omaha, Nebraska

Calvin Willhite, Ph.D.
Department of Toxic Substances Control
State of California

EXECUTIVE SUMMARY

Benzyl Alcohol – Oral Risk Assessment CAS # 100-51-6			
PARAMETER	LEVEL	UNITS	CALCULATED:
NOAEL (no-observed-adverse-effect level)	143	mg/kg-day	From a 2-year bioassay in mice.
Oral RfD (oral reference dose)	0.5	mg/kg-day	From a 2-year bioassay in mice.
TAC (total allowable concentration)	3	mg/L	For a 70 kg adult drinking 2 L/day, with a 20% source contribution for water
SPAC (single product allowable concentration)	0.3	mg/L	Based on 10 sources of benzyl alcohol in drinking water
STEL (short term exposure level)	10	mg/L	For a 10 kg child drinking 1 L/day
KEY STUDY	NTP. 1989. National Toxicology Program Toxicology and Carcinogenesis Studies of Benzyl Alcohol (CAS No. 100-51-6) in F344/N Rats and B6C3F1 Mice (Gavage Studies). NTP Technical Report 343. National Institutes of Health Publication No. 89-2599.		
CRITICAL EFFECT	The chronic study did not identify any statistically significant toxic responses to benzyl alcohol administration in either rats or mice to serve as the critical effect. At higher dose levels than were used in the chronic study, lethargy and progressively more severe neurotoxic responses with increasing dose were observed.		
UNCERTAINTY FACTORS	<ul style="list-style-type: none"> • 10x for interspecies extrapolation, as there are insufficient data to establish a data-derived uncertainty factor • 10x for intraspecies extrapolation, as there are insufficient data to establish a data-derived uncertainty factor • 1x for duration of exposure, as a lifetime exposure study was used as the key study • 1x for LOAEL to NOAEL extrapolation, as a NOAEL was used • 3x for database deficiencies, as there are no two-generation reproduction or standard developmental toxicity studies <p>The total uncertainty factor is, therefore, 300x.</p>		
TOXICITY SUMMARY	<p>Studies in rats and mice dosed by gavage with benzyl alcohol at levels up to 2,000 mg/kg-day resulted in progressive lethargy, sedation, and death. No associated histopathology was seen in these animals. There was no evidence of any cumulative toxic effect of benzyl alcohol exposure based on studies in rats and mice of 16 days to 2 years duration. Benzyl alcohol was not mutagenic in standard <i>in vitro</i> tests, and there was no evidence of cancer in rats or in mice after two years of exposure.</p> <p>Benzyl alcohol is rapidly absorbed and metabolized to benzoic acid in humans. With the exception of rare, mild sensitization reactions, a 4.5 mg/kg-day intravenous dose appears to be without adverse effect in adults. Medical use of benzyl alcohol as a preservative in flushing solutions for intravascular catheters and injectable medications resulted in metabolic acidosis, gasping respiration, and some deaths in low birth weight newborns. The problem was recognized and the use of benzyl alcohol as a preservative was severely limited in fluids used for these patients.</p>		
CONCLUSIONS	Benzyl alcohol is a relatively nontoxic compound in adults and children. Care must be taken not to give newborns, especially those of birth weight ≤ 2,500 g, an inadvertent parenteral dose that exceeds their immature metabolizing capabilities. The TAC, SPAC, and STEL levels for oral benzyl alcohol exposure derived in this assessment are considered protective of human health.		

1.0 INTRODUCTION

This document has been prepared to allow toxicological evaluation of the unregulated contaminant **benzyl alcohol** in drinking water, as an extractant from one or more drinking water system components evaluated under NSF/ANSI 61 (2002), or as a contaminant in a drinking water treatment chemical evaluated under NSF/ANSI 60 (2002). Both non-cancer and cancer endpoints have been considered, and risk assessment methodology developed by the U.S. Environmental Protection Agency (U.S. EPA) has been used.

Non-cancer endpoints are evaluated using the reference dose (RfD) approach (Barnes and Dourson, 1988; Dourson, 1994; U.S. EPA, 1993), which assumes that there is a threshold for these endpoints that will not be exceeded if appropriate uncertainty factors (Dourson et al., 1996) are applied to the highest dose showing no significant adverse effects. This highest dose is derived from human exposure data when available, but more often is derived from studies in laboratory animals. Either the no-observed-adverse-effect level (NOAEL) taken directly from the dose-response data, or the calculated lower 95% confidence limit on the dose resulting in an estimated 10% increase in response (the LED₁₀ or BMDL from benchmark dose programs) can be used (U.S. EPA, 2001). The lowest-observed-adverse-effect level (LOAEL) can also be used, with an additional uncertainty factor, although the benchmark dose approach is preferred in this case. The RfD is generally expressed in mg/kg-day. The RfD is defined by the U.S. EPA as “an estimate (with uncertainty spanning perhaps an order of magnitude) of a daily exposure to the human population (including sensitive subgroups) that is likely to be without an appreciable risk of deleterious effects during a lifetime” (Barnes and Dourson, 1988; U.S. EPA, 1993; U.S. EPA, 1999a).

NSF uses the RfD to derive three product evaluation criteria for non-cancer endpoints. The total allowable concentration (TAC), generally used to evaluate the results of extraction testing normalized to static at-the-tap conditions, is defined as the RfD multiplied by the 70 kg weight of an average adult assumed to drink 2 liters of water per day. A relative source contribution (RSC), to ensure that the RfD is not exceeded when food and other non-water sources of exposure to the chemical are considered, is also applied in calculating the TAC. The relative source contribution should be data derived, if possible. Alternately, a 20% default contribution for water can be used (U.S. EPA, 1991a). The TAC calculation is then as follows:

$$\text{TAC (mg/L)} = \frac{[\text{RfD (mg/kg-day)} \times 70 \text{ kg}] - [\text{total contribution of other sources (mg/day)}]}{2\text{L/day}}$$

or

$$\text{TAC (mg/L)} = \frac{\text{RfD (mg/kg-day)} \times 70 \text{ kg}}{2\text{L/day}} \times 0.2 \text{ (RSC)}$$

The single product allowable level (SPAC), used for water treatment chemicals and for water contact materials normalized to flowing at-the-tap conditions, is the TAC divided by the estimated total number of sources of the substance in the drinking water treatment and distribution system. In the absence of source data, a default multiple source factor of 10 is used.